Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 8/20 | 0.53 |
| ▸ | ACE | P12821 | 8/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246178 | 1.00 | FOLH1 (0.58) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL9847998 | 0.87 | FOLH1 (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL9847993 | 0.87 | FOLH1 (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5738141 | 0.87 | FOLH1 (0.61) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL12869808 | 0.87 | FOLH1 (0.61) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL22612664 | 0.85 | FOLH1 (0.60) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL29444963 | 0.85 | FOLH1 (0.60) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL27973852 | 0.84 | ACE (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL6769407 | 0.84 | FOLH1 (0.51) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5869992 | 0.83 | FOLH1 (0.74) | FOLH1MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104860-A2 | ACTIVATABLE BINDING MOLECULE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| EP-4376894-A1 | CONJUGATING REAGENTS AND CONJUGATES THEREOF | Cambridge Enterprise Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| CN-117088902-A | Preparation method of boron carrying agent by one-pot method | 苏州博锐创合医药有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116194156-A | PET-CT imaging method, contrast medium and pharmaceutical composition for use in said imaging method | 艾迪珀斯股份公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2023023170-A1 | SYSTEMS, METHODS, AND COMPUTER READABLE MEDIA FOR PARAMETRIC FDG PET QUANTIFICATION, SEGMENTATION AND CLASSIFICATION OF ABNORMALITIES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023006782-A1 | CONJUGATING REAGENTS AND CONJUGATES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-02-02 | — | — | WO | disclosed |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130149243-A1 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| CN-102336678-A | Method for preparing 18F-FET | CHINESE PLA GENERAL HOSPITAL | 2012-02-01 | — | — | CN | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149243-A1 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | GLUL, SLC18A2, SLC1A2 | FOLH1 12/4885MME 2364/4885ACE 2298/4885 |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | CASP5, SLC1A5, CTSZ | FOLH1 102/4885MME 724/4885ACE 1736/4885 |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | FOLH1 105/4885MME 550/4885ACE 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.